The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide.


Bumetanide is increasingly being used for experimental treatment of brain disorders, including neonatal seizures, epilepsy, and autism, because the neuronal Na-K-Cl cotransporter NKCC1, which is inhibited by bumetanide, is implicated in the pathophysiology of such disorders. However, use of bumetanide for treatment of brain disorders is associated with… (More)
DOI: 10.1016/j.ejphar.2014.11.019


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.